Effector CD8(+ )T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia. Jan 2012 - Int J Hyperthermia; 28(1):1464-5157 [PMID:22235780] [Mace TA] [Zhong L] [Kokolus KM] [Repasky EA]
Differentiation of CD8+ T cells into effector cells is enhanced by physiological range hyperthermia. Nov 2011 - J. Leukoc. Biol.; 90(5):1938-3673 [PMID:21873456] [Mace TA] [Zhong L] [Kilpatrick C] [Zynda E] [Lee CT] [Capitano M] [Minderman H] [Repasky EA]
Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Mar 2010 - Immunol. Res.; 46(1-3):1559-0755 [PMID:19756410] [Peer AJ] [Grimm MJ] [Zynda ER] [Repasky EA]
Hyperthermia as an immunotherapy strategy for cancer. Jun 2009 - Curr Opin Investig Drugs; 10(6):2040-3429 [PMID:19513944] [Skitzki JJ] [Repasky EA] [Evans SS]
Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Jan 2008 - Int J Hyperthermia; 24(1):0265-6736 [PMID:18214768] [Dayanc BE] [Beachy SH] [Ostberg JR] [Repasky EA]
Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin. Oct 2007 - Int J Hyperthermia; 23(6):0265-6736 [PMID:17952765] [Xu Y] [Choi J] [Hylander B] [Sen A] [Evans SS] [Kraybill WG] [Repasky EA]
Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Nov 2005 - Cancer Immunol. Immunother.; 55(3):0340-7004 [PMID:15864585] [Ostberg JR] [Repasky EA]
The anti-tumor effect of interleukin-12 is enhanced by mild (fever-range) thermal therapy. Sep 2005 - Immunol. Invest.; 34(3):0882-0139 [PMID:16136786] [Pritchard MT] [Wolf SF] [Kraybill WF] [Repasky EA]
Thermal regulation of dendritic cell activation and migration from skin explants. Aug 2003 - Int J Hyperthermia; 19(5):0265-6736 [PMID:12944167] [Ostberg JR] [Kabingu E] [Repasky EA]
A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. May 2002 - Int J Hyperthermia; 18(3):0265-6736 [PMID:12028640] [Kraybill WG] [Olenki T] [Evans SS] [Ostberg JR] [O'Leary KA] [Gibbs JF] [Repasky EA]
Use of mild, whole body hyperthermia in cancer therapy. Aug 2000 - Immunol. Invest.; 29(2):0882-0139 [PMID:10854182] [Ostberg JR] [Repasky EA]
Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice. Jul 1999 - Infect Dis Obstet Gynecol; 7(1-2):1064-7449 [PMID:10231015] [Repasky EA] [Tims E] [Pritchard M] [Burd R]
